Fulcrum Therapeutics, Inc.’s Free Cash Flow Yield at a glance
Fulcrum Therapeutics, Inc. reports free cash flow yield of -0.86% for Dec 2024. The prior period recorded -22.1% (Dec 2023). Year over year the metric moved +21.2 pts (+96.1%). The rolling three-period average stands at -17.7%. Data last refreshed Dec 7, 2025, 2:49 AM.
Latest reading
-0.86% · Dec 2024
YoY movement
+21.2 pts (+96.1%)
Rolling average
-17.7%
Current Free Cash Flow Yield
-0.86%
+21.2 pts
+96.1%
Rolling average
-17.7%
Latest Value
-0.86%
Dec 2024
YoY Change
+21.2 pts
Absolute
YoY Change %
+96.1%
Rate of change
3-Period Avg
-17.7%
Smoothed
Narrative signal
Fulcrum Therapeutics, Inc.’s free cash flow yield stands at -0.86% for Dec 2024. Year-over-year, the metric shifted by +21.2 pts, translating into a +96.1% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How free cash flow yield shapes Fulcrum Therapeutics, Inc.'s story
As of Dec 2024, Fulcrum Therapeutics, Inc. reports free cash flow yield of -0.86%. Use free cash flow yield to benchmark valuation using cash generation rather than earnings, highlighting capital return capacity.
Valuation through cash generation
High free cash flow yields often indicate attractive pricing relative to cash generation, assuming cash flows are sustainable.
Compare with payout commitments
Pair yield with dividend payout to gauge how much free cash flow remains for buybacks, debt reduction, or reinvestment.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Gross Margin
98%
Operating Margin
-27.4%
Net Profit Margin
-12.2%
Return on Equity
-4%
Return on Assets
-3.7%
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Fulcrum Therapeutics, Inc. (FULC) FAQs
Answers tailored to Fulcrum Therapeutics, Inc.’s free cash flow yield profile using the latest Financial Modeling Prep data.
What is Fulcrum Therapeutics, Inc.'s current free cash flow yield?
As of Dec 2024, Fulcrum Therapeutics, Inc. reports free cash flow yield of -0.86%. This reading reflects the latest filings and price data for FULC.
How is Fulcrum Therapeutics, Inc.'s free cash flow yield trending year over year?
Year-over-year, the figure shifts by +21.2 pts (+96.1%). Pair this context with revenue growth and free cash flow signals to gauge momentum for FULC.
Why does free cash flow yield matter for Fulcrum Therapeutics, Inc.?
Free cash flow yield compares free cash flow to market capitalization to evaluate cash generation versus price. For Fulcrum Therapeutics, Inc., operating within Healthcare — Biotechnology, tracking this metric helps benchmark management's execution against close competitors.
Is Fulcrum Therapeutics, Inc.'s free cash flow yield above its recent average?
Fulcrum Therapeutics, Inc.'s rolling three-period average sits at -17.7%. Comparing the latest reading of -0.86% to that baseline highlights whether momentum is building or fading for FULC.
How frequently is Fulcrum Therapeutics, Inc.'s free cash flow yield refreshed?
Data for FULC was last refreshed on Dec 7, 2025, 2:49 AM and updates automatically every 24 hours, keeping your valuation inputs current.